Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model

References

• BuistASMcBurnieMAVollmerWMBOLD Collaborative Research GroupInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523
   PubMed Web of Science ®Google Scholar
• GOLD [homepage on the Internet]Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2015 Available from: http://www.goldcopd.com/Accessed March 2015
   Google Scholar
• NagaiKMakitaHSuzukiMHokkaido COPD Cohort Study InvestigatorsDifferential changes in quality of life components over 5 years in chronic obstructive pulmonary disease patientsInt J Chron Obstruct Pulmon Dis20151074575725914531
   PubMed Web of Science ®Google Scholar
• DalalAALiuFRiedelAACost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009Int J Chron Obstruct Pulmon Dis2011653354222069365
   PubMed Web of Science ®Google Scholar
• FordESMurphyLBKhavjouOGilesWHHoltJBCroftJBTotal and state-specific medical and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and projections through 2020Chest20151471314525058738
   PubMed Web of Science ®Google Scholar
• GSKANORO™ ELLIPTA^® [prescribing information]2014 Available from: https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDFAccessed June 2015
   Google Scholar
• GSK [webpage on the Internet]ANORO™ ELLIPTA^® summary of product characteristics2014 Available from: http://www.medicines.org.uk/emc/medicine/28949#INDICATIONSAccessed June 2015
   Google Scholar
• BlairHADeeksEDUmeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary diseaseDrugs2015751617425398674
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• GOLDGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2013 Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.201204-0596PPAccessed February 2017
   Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• ShavelleRMPaculdoDRKushSJManninoDMStraussDJLife expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up StudyInt J Chron Obstruct Pulmon Dis2009413714819436692
   PubMedGoogle Scholar
• DietteGBDalalAAD’SouzaAOLunacsekOENagarSPTreatment patterns of chronic obstructive pulmonary disease in employed adults in the United StatesInt J Chron Obstruct Pulmon Dis20151041542225759574
   PubMed Web of Science ®Google Scholar
• GreenMENatajaranNO’DonnellDEChronic obstructive pulmonary disease in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance NetworkCMAJ Open201531E15E22
   Google Scholar
• JonesCANORO™ ELLIPTA™ Umeclidinium/Vilanterol Inhalation Powder 62.5/25 mcg2013 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM368638.pdfAccessed June 2015
   Google Scholar
• SpencerMBriggsAHGrossmanRFRanceLDevelopment of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseasePharmacoeconomics200523661963715960557
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• KochanekKDXuJMurphySLMininoAMKungHCDeaths: final data for 2009Natl Vital Stat Rep20116031116
   PubMedGoogle Scholar
• Boehringer IngelheimSPIRIVA^® HandiHaler^® [prescribing information]2014 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdfAccessed September 2015
   Google Scholar
• Boehringer IngelheimCombivent^® [prescribing information]2014 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+Respimat/CMVTRSPT.pdfAccessed September 2015
   Google Scholar
• Wolters Kluwer [webpage on the Internet]Medi-Span^® 2.0 Price Rx Electronic Version2015Indianapolis, INWolters Kluwer Available from: https://pricerx.medispan.com/Accessed February 8, 2016
   Google Scholar
• YuAPYangHWuEQSetyawanJMocarskiMBlumSIncremental third-party costs associated with COPD exacerbations: a retrospective claims analysisJ Med Econ201114331532321500975
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention [webpage on the Internet]Adult Appropriate Antibiotic Use Summary: Physician Information Sheet Available from: http://www.cdc.gov/getsmart/community/materials-references/print-materials/hcp/adult-approp-summary.htmlAccessed September 2015
   Google Scholar
• IngenixThe Essential RBRVS (2013): A Comprehensive Listing of RBRVS Values for CPT and HCPCS CodesNew York, NYSt. Anthony Publishing2013
   Google Scholar
• US Bureau of Labor StatisticsUS Department of Labor [webpage on the Internet]US city average, not seasonally adjusted medical care Available from: http://data.bls.gov/PDQ/outside.jsp?survey=cuAccessed October 2015
   Google Scholar
• HettleRWoutersHAyresJCost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and BelgiumRespir Med2012106121722173323040833
   PubMed Web of Science ®Google Scholar
• HoogendoornMKappelhoffBSOverbeekJAWoutersEFRutten-van MolkenMPWhich long-acting bronchodilator is most cost-effective for the treatment of COPD?Neth J Med201270835736423065983
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MolkenMPMonzBUFitzGeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health200581324615841892
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
   PubMed Web of Science ®Google Scholar
• EklundOAfzalFBorgstromFCost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in SwedenCost Eff Resour Alloc2015131326288574
   PubMed Web of Science ®Google Scholar
• WurstKEPunekarYSShuklaATreatment evolution after COPD diagnosis in the UK primary care settingPLoS One201499e10529625180802
   PubMed Web of Science ®Google Scholar
• MiyazakiMNakamuraHTakahashiSKeio COPD Comorbidity Research (K-CCR) GroupThe reasons for triple therapy in stable COPD patients in Japanese clinical practiceInt J Chron Obstruct Pulmon Dis2015101053105926082629
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• HoogendoornMFeenstraTLAsukaiYCost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosValue Health201417552553625128045
   PubMed Web of Science ®Google Scholar
• HuurneKKMovigKvan der ValkPvan der PalenJBrusse-KeizerMDifferences in adherence to common inhaled medications in COPDCOPD201512664364825775100
   PubMedGoogle Scholar
• TrudoFKernDMDavisJRComparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatmentsInt J Chron Obstruct Pulmon Dis2015102055206626451101
   PubMed Web of Science ®Google Scholar
• American Medical Association (AMA)Current Procedural Terminology (CPT)Chicago, ILAMA Press2013
   Google Scholar